Enrollment in a South Carolina Medicaid waiver program for children with autism spectrum disorder was largely equitable between neighborhoods, although privileged neighborhoods had higher enrollment in years of inequity.
Treatment with methylphenidate affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder.
The compensatory strategies employed by individuals with autism spectrum disorder might be a barrier to an official, timely diagnosis of autism, and might have negative consequences on individual’s mental health and well-being.
The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.
The risk factors for tardive dyskinesia in patients taking antipsychotics include age, comorbid diagnoses, and high medication dosages.
Variation in autism spectrum disorder occurrence may be due to genetic influences, rather than maternal or environmental effects.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
Top-down regulatory mechanisms influenced whether or not children with autism spectrum disorder expressed atypical behavioral responses to sensory stimuli.
Adhansia XR (methylphenidate HCl extended-release capsules) for the treatment of attention deficit hyperactivity disorder in patients aged 6 years and older, has launched.
Current guidelines include recommendations on how to prescribe methylphenidate, but lack of recommendations regarding the long-term use of the drug.